The Best Quantum Computing Stocks to Buy in 2026

IBM is presented as a steadier quantum computing play, with revenue and EPS expected to grow at 5% CAGRs from 2025 to 2028, alongside a 2.9% forward dividend yield and a valuation of 20x next year's earnings. IonQ is the higher-risk, higher-upside option, with revenue rising from $2 million in 2021 to $130 million in 2025 and projected to reach $600 million by 2028, though it remains unprofitable and trades at 28x 2028 sales. The article is broadly constructive on quantum computing adoption, but the content is primarily comparative commentary rather than new company-specific news.

Analysis

The market is underappreciating the bifurcation between “quantum as R&D spend” and “quantum as monetizable enterprise infrastructure.” IBM’s edge is not the lab result itself; it is the distribution channel. If quantum becomes a feature inside hybrid cloud workflows, IBM can re-rate from a pure legacy compounder into an option on a new compute layer without needing quantum to carry the P&L in the near term.

IONQ’s setup is more asymmetric, but the path to value creation is narrower: government and regulated-industry procurement are the bridge customers, not broad enterprise adoption. That means the stock is likely to trade on contract cadence, backlog conversion, and any evidence that trapped-ion systems are becoming the default for high-precision workloads. The second-order winner could be cloud and defense integrators that package access and workflow tooling around quantum hardware, rather than the hardware vendors alone.

The main risk is that the market is extrapolating technology superiority into commercial durability. Quantum spend can remain strategically important while still producing poor economic returns for years; if error-correction milestones slip, enthusiasm will compress quickly because the multiple is already discounting meaningful future scale. For IBM, the risk is more subtle: quantum optionality may obscure slower core growth, while for IONQ the risk is dilution and capital intensity if revenue ramps slower than the estimate path.

Consensus seems too comfortable treating this as a linear adoption story. The more likely winning structure is a long-duration, winner-take-most ecosystem where software orchestration, cloud access, and government procurement matter more than raw QPU counts. That favors IBM as the lower-volatility “platform call option,” while IONQ remains the higher-beta expression with much greater sensitivity to execution and financing conditions.

Key Decisions for Investors

• Long IBM on a 6-12 month horizon as a hybrid-cloud compounder with embedded quantum optionality; upside is steadier multiple support and dividend carry, while downside is limited by core cash generation.
• Speculative long IONQ only on pullbacks or after contract/backlog confirmation; use a smaller position size given dilution risk and high sensitivity to commercialization timing.
• Pair trade: long IBM / short IONQ for investors wanting quantum exposure with lower drawdown risk; thesis is that platform monetization will outrun pure-play commercialization, with materially better risk-adjusted return.
• For more aggressive accounts, consider IONQ call spreads 9-15 months out to express upside to contract wins while capping premium burn if milestones slip.
• Avoid chasing broad quantum basket exposure until there is clearer evidence of enterprise conversion; the better trade is selective exposure to the incumbent platform winner rather than the highest story beta.